To challenge the target of "unable to make a drug", Huadong Medicine and British Silicon Intelligence cooperate to develop innovative anti-tumor drugs
September 09, 2021
On September 8, 2021, Huadong Medicine (SZ.000963) and Insilico Medicine announced today that they have established a partnership to jointly accelerate the research and development of innovative small molecule drugs in the oncology field. According to the agreement, Huadong Medicine and British Silicon Intelligence will launch a new drug discovery project under the joint collaboration of the scientific research teams of both parties. The project team will interfere with protein-protein interactions to specifically target the "non-drugable" targets that regulate tumor growth, and use Huadong Medicine’s advanced innovative drug discovery and screening and characterization platform, combined with Anglo Silicon’s end-to-end artificial intelligence The smart drug R&D platform, especially the small molecule generation platform Chemistry42, designs and screens potential first-in-class (FIC) drug molecules with novelty, high activity and high druggability. Huadong Medicine is a listed pharmaceutical company integrating R&D, manufacturing, sales and commerce. It has more than 10,000 employees in China, sales channels covering tens of thousands of large and medium-sized hospitals, and more than 1,000 R&D personnel, covering drug discovery, Pre-clinical research, clinical research, CMC and various R&D links of registration. Huadong Medicine focuses on innovation and transformation strategies, and is committed to concentrating advantages and R&D resources, with the help of partners’ advanced technology and means, to build a forward-looking anti-tumor, endocrine/metabolic and autoimmune disease innovative product R&D pipeline. British Silicon Intelligence is an end-to-end innovative drug research and development company driven by artificial intelligence. Its self-developed small molecule compound design and generation platform Chemistry42 combines artificial intelligence technology with computational and medicinal chemistry methods to efficiently generate specific targets New molecular structures with predefined characteristics help to screen and obtain drug molecules that can be verified by in vitro and in vivo studies, and quickly realize from the discovery of emerging compounds to the determination of clinical compounds. Dr. Liu Dongzhou, Chief Scientific Officer of Huadong Medicine and General Manager of Innovative Drug R&D Center, said: “Introducing artificial intelligence into new drug research and development can greatly improve the efficiency of drug research and development, and can effectively speed up the time from drug design, discovery, preclinical research and development to clinical development and reduce R&D costs. We look forward to cooperating with the leading international AI company British Silicon Intelligence to leverage their respective advantages to develop potential FIC drug molecules to meet the ever-increasing clinical medical needs, while providing patients with more superior and even disruptive Treatment options." said Dr. Feng Ren, Chief Scientific Officer and Head of Drug R&D of INT Silicon: “Complementary advantages and cooperative innovation are increasingly becoming the trend of new drug R&D. I am honored to cooperate with Huadong Medicine to give full play to the advanced generation of INT Silicon The advantages of the chemical platform Chemistry42 and Huadong Medicine’s powerful target verification and screening platform, jointly challenge the traditional "unable to drug" targets such as protein-protein interactions, and more efficiently solve unmet clinical needs."
